Ignyta (RXDX) versus Cascadian Therapeutics (CASC) Head-To-Head Review

Cascadian Therapeutics (NASDAQ: CASC) and Ignyta (NASDAQ:RXDX) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, valuation, dividends, profitability, risk and analyst recommendations.

Earnings and Valuation

How to Become a New Pot Stock Millionaire

This table compares Cascadian Therapeutics and Ignyta’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Cascadian Therapeutics N/A N/A -$56.93 million ($1.34) -7.45
Ignyta N/A N/A -$103.63 million ($2.71) -9.96

Ignyta is trading at a lower price-to-earnings ratio than Cascadian Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Cascadian Therapeutics and Ignyta’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Cascadian Therapeutics N/A -43.53% -40.90%
Ignyta N/A -113.09% -68.72%

Institutional and Insider Ownership

81.4% of Cascadian Therapeutics shares are owned by institutional investors. Comparatively, 72.3% of Ignyta shares are owned by institutional investors. 1.1% of Cascadian Therapeutics shares are owned by insiders. Comparatively, 13.1% of Ignyta shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of current recommendations for Cascadian Therapeutics and Ignyta, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cascadian Therapeutics 1 2 2 0 2.20
Ignyta 0 4 1 0 2.20

Cascadian Therapeutics currently has a consensus price target of $7.00, suggesting a potential downside of 29.86%. Ignyta has a consensus price target of $26.40, suggesting a potential downside of 2.15%. Given Ignyta’s higher probable upside, analysts plainly believe Ignyta is more favorable than Cascadian Therapeutics.

Risk and Volatility

Cascadian Therapeutics has a beta of 3.79, indicating that its share price is 279% more volatile than the S&P 500. Comparatively, Ignyta has a beta of 184.87, indicating that its share price is 18,387% more volatile than the S&P 500.

Summary

Cascadian Therapeutics beats Ignyta on 7 of the 10 factors compared between the two stocks.

About Cascadian Therapeutics

Cascadian Therapeutics, Inc., formerly Oncothyreon Inc., is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company’s clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor. The Company’s ONT-10 is a therapeutic vaccine targeting the Mucin 1 peptide antigen (MUC1). The Company is engaged in developing preclinical product candidates in oncology using its Checkpoint kinase 1 (Chk1) kinase inhibitor and protocell technology. The Company completed the evaluation of approximately two dosing cohorts in its Phase Ib trial of ONT-10 in combination with the anti-CD27 T-cell agonist antibody varlilumab in collaboration with other company. The Company has completed Phase I trial of ONT-380, with both dose-escalation and expansion components. The Company has initiated Phase Ib trials of ONT-380.

About Ignyta

Ignyta, Inc. is a biotechnology company. The Company is focused on precision medicine in oncology. The Company is pursuing an integrated therapeutic (Rx) and companion diagnostic (Dx) strategy for treating cancer patients. The Company’s pipeline includes various compounds, such as entrectinib, RXDX-105, taladegib and RXDX-106. Entrectinib is an orally bioavailable, central nervous system (CNS)-active, small molecule tyrosine kinase inhibitor directed to the tropomyosin receptor kinase (TRK) family of tyrosine kinase receptors (TRKA, TRKB and TRKC), ROS1 and anaplastic lymphoma kinase (ALK) proteins. RXDX-105 is an orally bioavailable, vascular endothelial growth factor receptor (VEGFR)-sparing, small molecule tyrosine kinase inhibitor of rearranged during transfection (RET). Taladegib is an orally bioavailable, small molecule hedgehog/smoothened antagonist. RXDX-106 is a pseudo-irreversible, small molecule inhibitor of TYRO3, AXL and MER (collectively TAM), and c-MET.

Receive News & Ratings for Cascadian Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cascadian Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Whiting Petroleum  Sets New 52-Week High and Low at $40.47
Whiting Petroleum Sets New 52-Week High and Low at $40.47
SilverBow Resources  Reaches New 52-Week High and Low at $34.76
SilverBow Resources Reaches New 52-Week High and Low at $34.76
Financial Comparison: Service Co. International  versus Yelp
Financial Comparison: Service Co. International versus Yelp
Critical Contrast: Morgan Stanley  and Its Competitors
Critical Contrast: Morgan Stanley and Its Competitors
Barfresh Food Group  vs. Lamb Weston  Head to Head Survey
Barfresh Food Group vs. Lamb Weston Head to Head Survey
Royal Bank of Canada Increases American Express  Price Target to $86.00
Royal Bank of Canada Increases American Express Price Target to $86.00


© 2006-2018 Ticker Report. Google+.